SAB Biotherapeutics (SABS) Interest Expenses (2021 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Interest Expenses data on file, last reported at $27.6 million in Q1 2026.

• Quarterly Interest Expenses rose 10453.66% year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (up 10453.66% YoY) and the FY2025 annual result came in at $26.1 million, up 2098.01% from the prior year.
• Interest Expenses grew to $27.6 million in Q1 2026, from $62331.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $27.6 million in Q1 2026 to a low of -$636608.0 in Q4 2022.
• A 5-year average of $2.0 million and a median of $261105.0 in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses slumped 1060.56% — and 2026, when it soared 10453.66%.
• Tracing SABS's Interest Expenses over 5 years: stood at -$636608.0 in 2022, then surged by 112.23% to $77879.0 in 2023, then plunged by 482.7% to -$298046.0 in 2024, then surged by 120.91% to $62331.0 in 2025, then surged by 44109.37% to $27.6 million in 2026.
• The last three Interest Expenses figures came in at $27.6 million (Q1 2026), $62331.0 (Q4 2025), and $728650.0 (Q3 2025), per Business Quant data.